Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor’s current focus is on developing exosomes capable of delivering nucleic acids as well as proteins to treat or prevent a variety of diseases.
LifeSci Advisors, LLC
Corporate & Research Headquarters
Capricor Therapeutics, Inc.
10865 Road to the Cure
San Diego, CA 92121